279 related articles for article (PubMed ID: 20424485)
1. Local delivery of angiotensin II receptor blockers into the kidney passively attenuates inflammatory reactions during the early phases of streptozotocin-induced diabetic nephropathy through inhibition of calpain activity.
Kamal F; Yanakieva-Georgieva N; Piao H; Morioka T; Oite T
Nephron Exp Nephrol; 2010; 115(3):e69-79. PubMed ID: 20424485
[TBL] [Abstract][Full Text] [Related]
2. Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis.
Mahmood J; Khan F; Okada S; Kumagai N; Morioka T; Oite T
Kidney Int; 2006 Nov; 70(9):1591-8. PubMed ID: 16985512
[TBL] [Abstract][Full Text] [Related]
3. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
5. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.
Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME
Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758
[TBL] [Abstract][Full Text] [Related]
6. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
[TBL] [Abstract][Full Text] [Related]
7. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blocker inhibits p27Kip1 expression in glucose-stimulated podocytes and in diabetic glomeruli.
Xu ZG; Yoo TH; Ryu DR; Cheon Park H; Ha SK; Han DS; Adler SG; Natarajan R; Kang SW
Kidney Int; 2005 Mar; 67(3):944-52. PubMed ID: 15698433
[TBL] [Abstract][Full Text] [Related]
9. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
[TBL] [Abstract][Full Text] [Related]
10. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats.
Motawi TK; El-Maraghy SA; Senousy MA
J Biochem Mol Toxicol; 2013 Jul; 27(7):378-87. PubMed ID: 23733546
[TBL] [Abstract][Full Text] [Related]
12. Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy.
Vieitez P; Gómez O; Uceda ER; Vera ME; Molina-Holgado E
J Renin Angiotensin Aldosterone Syst; 2008 Jun; 9(2):96-102. PubMed ID: 18584585
[TBL] [Abstract][Full Text] [Related]
13. FPS-ZM1 and valsartan combination protects better against glomerular filtration barrier damage in streptozotocin-induced diabetic rats.
Sanajou D; Ghorbani Haghjo A; Argani H; Roshangar L; Ahmad SNS; Jigheh ZA; Aslani S; Panah F; Rashedi J; Mesgari Abbasi M
J Physiol Biochem; 2018 Aug; 74(3):467-478. PubMed ID: 29948786
[TBL] [Abstract][Full Text] [Related]
14. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy.
Lee FT; Cao Z; Long DM; Panagiotopoulos S; Jerums G; Cooper ME; Forbes JM
J Am Soc Nephrol; 2004 Aug; 15(8):2139-51. PubMed ID: 15284299
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin receptor blockade attenuates glomerulosclerosis progression by promoting VEGF expression and bone marrow-derived cells recruitment.
Song SM; Wang CC; Qi SH; Xing L; Yang BF; Oite T; Li B
Nephrol Dial Transplant; 2012 Jul; 27(7):2712-9. PubMed ID: 22140134
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Hofni A; El-Moselhy MA; Taye A; Khalifa MM
Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
[TBL] [Abstract][Full Text] [Related]
18. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor blocker ameliorates uncoupled endothelial nitric oxide synthase in rats with experimental diabetic nephropathy.
Satoh M; Fujimoto S; Arakawa S; Yada T; Namikoshi T; Haruna Y; Horike H; Sasaki T; Kashihara N
Nephrol Dial Transplant; 2008 Dec; 23(12):3806-13. PubMed ID: 18596126
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats.
Kato S; Luyckx VA; Ots M; Lee KW; Ziai F; Troy JL; Brenner BM; MacKenzie HS
Kidney Int; 1999 Sep; 56(3):1037-48. PubMed ID: 10469372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
